APEIRON Biologics AG:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:APEIRON Biologics AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3040
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
APEIRON Biologics AG (APEIRON) is a clinical-stage biotechnology company that concentrates on the development of biological and immunological solutions for the treatment of various cancers. The company’s pipeline products include APN01, APN301, APN311, APN401, APN411, APN421 and APN431. Its APN311 is an antibody-based therapy used for the treatment of high-risk neuroblastoma. APEIRON’s APN301 is an anti-GD2 antibody-IL2 fusion protein used for intratumoral application in GD2+ pediatric cancers. The company carries out projects in biotherapy and cancer immune field. APEIRON is headquartered in Vienna, Austria.

APEIRON Biologics AG – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
APEIRON Biologics AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Evotec and APEIRON Biologics Enters into Licensing Agreement with Sanofi 10
Evotec Enters Into Research Agreement With Apeiron Biologics For Cancer Immunotherapy 11
Licensing Agreements 12
APEIRON Biologics Enters into Licensing Agreement with Molecular Biotechnology and Medical University of Vienna 12
Apeiron Biologics Enters into Licensing Agreement with Columbia University 13
Apeiron Biologics Enters into Licensing Agreement with Medison Pharma for APN311 14
Apeiron Biologics Enters into Licensing Agreement with Gen Ilac for APN311 15
Paladin Labs Enters Into Licensing Agreement With Apeiron Biologics For APN311 16
Asset Transactions 17
EUSA Pharma Acquires commercialization rights to Isqette from APEIRON Biologics 17
APEIRON Biologics AG – Key Competitors 18
APEIRON Biologics AG – Key Employees 19
APEIRON Biologics AG – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Government and Public Interest 21
Aug 28, 2017: Investment Plan for Europe: EIB grants financing to Apeiron 21
Product News 22
12/18/2017: Apeiron Announces Publication of Clinical Data With Anti-GD2 Antibody Demonstrating Efficacy in Relapsed & Refractory High-Risk Neuroblastoma 22
10/13/2017: APEIRON Strengthens Management Board with Industry Expert Peter Llewellyn-Davies as New Chief Financial Officer 23
05/09/2017: European Commission approves the only immunotherapy for high-risk neuroblastoma, bringing hope to thousands of children affected by a rare and devastating form of cancer 24
03/27/2017: EUSA Pharma and Apeiron Biologics Receive Positive CHMP Opinion for Dinutuximab Beta for the Treatment of High-risk Neuroblastoma in Europe 25
03/23/2017: APEIRON Biologics Receives CHMP Positive Opinion For Dinutuximab Beta 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Key Facts 2
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
APEIRON Biologics AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
APEIRON Biologics AG, Deals By Therapy Area, 2012 to YTD 2018 8
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Evotec and APEIRON Biologics Enters into Licensing Agreement with Sanofi 10
Evotec Enters Into Research Agreement With Apeiron Biologics For Cancer Immunotherapy 11
APEIRON Biologics Enters into Licensing Agreement with Molecular Biotechnology and Medical University of Vienna 12
Apeiron Biologics Enters into Licensing Agreement with Columbia University 13
Apeiron Biologics Enters into Licensing Agreement with Medison Pharma for APN311 14
Apeiron Biologics Enters into Licensing Agreement with Gen Ilac for APN311 15
Paladin Labs Enters Into Licensing Agreement With Apeiron Biologics For APN311 16
EUSA Pharma Acquires commercialization rights to Isqette from APEIRON Biologics 17
APEIRON Biologics AG, Key Competitors 18
APEIRON Biologics AG, Key Employees 19

List of Figures
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
APEIRON Biologics AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[APEIRON Biologics AG:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • CBR Systems Inc-製薬・医療分野:企業M&A・提携分析
    Summary CBR Systems Inc (CBR), a subsidiary of AMAG Pharmaceuticals Inc is a stem cell company that offers newborn stem cells. The company designs and implements technologies and processes for cord blood banking. It offers cord blood banking service that stores newborn's umbilical cord blood; and co …
  • Madrigal Pharmaceuticals Inc (MDGL):製薬・医療:M&Aディール及び事業提携情報
    Summary Madrigal Pharmaceuticals Inc (Madrigal), formerly, Synta Pharmaceuticals Corp is a biopharmaceutical company focused on the development and commercialization of novel therapeutic candidates for the treatment of liver, cardiovascular and metabolic diseases. Its lead product candidate, MGL-319 …
  • Copenhagen Airports AS:企業の戦略・SWOT・財務情報
    Copenhagen Airports AS - Strategy, SWOT and Corporate Finance Report Summary Copenhagen Airports AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Shinva Medical Instrument Co Ltd (600587):企業の財務・戦略的SWOT分析
    Shinva Medical Instrument Co Ltd (600587) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • HD Supply Inc (HDS):企業の財務・戦略的SWOT分析
    HD Supply Inc (HDS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • MISC Berhad:企業の戦略・SWOT・財務情報
    MISC Berhad - Strategy, SWOT and Corporate Finance Report Summary MISC Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Taylor Communications Inc:企業の戦略的SWOT分析
    Taylor Communications Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Harte Hanks Inc (HHS):企業の財務・戦略的SWOT分析
    Harte Hanks Inc (HHS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • ALLETE Inc (ALE)-エネルギー分野:企業M&A・提携分析
    Summary ALLETE, Inc. (ALLETE) is an energy company that operates varied businesses in the energy sector. It has interests in mining facilities; electricity generation, transmission, and distribution assets; and water management businesses. It provides energy in the upper Midwest in the US; and inves …
  • Merge Healthcare Inc:医療機器:M&Aディール及び事業提携情報
    Summary Merge Healthcare Inc (Merge Technologies), a subsidiary of International Business Machines Corp, is a medical technology company that offers advanced solutions specifically designed for healthcare. The company's solutions include cardiology, orthopedics, interoperability, radiology, eye care …
  • China National Chemical Corp:石油・ガス:M&Aディール及び事業提携情報
    Summary China National Chemical Corp (ChemChina) is a state-owned enterprise that develops and markets chemicals. The company offers chemical materials and specialty chemicals, agrochemicals, oil processing and refining products, basic chemicals, and rubber products. ChemChina also manufactures equi …
  • NACHI-FUJIKOSHI CORP.:企業の戦略・SWOT・財務情報
    NACHI-FUJIKOSHI CORP. - Strategy, SWOT and Corporate Finance Report Summary NACHI-FUJIKOSHI CORP. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Carrizo Oil & Gas Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Carrizo Oil & Gas Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Carrizo Oil & Gas Inc (Carrizo) is an independent oil and gas company, which carries out exploration, development and production of oil and natural gas from several resources plays. It has pres …
  • LeasePlan Corporation N.V.:戦略・SWOT・企業財務分析
    LeasePlan Corporation N.V. - Strategy, SWOT and Corporate Finance Report Summary LeasePlan Corporation N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Bankinter Banca Privada:企業の戦略・SWOT・財務情報
    Bankinter Banca Privada - Strategy, SWOT and Corporate Finance Report Summary Bankinter Banca Privada - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Delcath Systems Inc (DCTH):製薬・医療:M&Aディール及び事業提携情報
    Summary Delcath Systems Inc (Delcath) specializes in developing percutaneous perfusion technologies to treat primary and metastatic liver cancers. Its patented drug delivery platform delivers ultra-high doses of anti-cancer drugs to the liver, while preventing them from entering the patient's bloods …
  • The Andersons Inc (ANDE):企業の財務・戦略的SWOT分析
    The Andersons Inc (ANDE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • InTouch Technologies Inc-医療機器分野:企業M&A・提携分析
    Summary InTouch Technologies Inc (InTouch Health) is a healthcare technology company that provides Telehealth Network, comprised of telehealth systems, clinical workflow solutions, software and managed services to healthcare systems and hospitals for the delivery of clinical care. The company’s tele …
  • Lamprell Plc (LAM):企業の財務・戦略的SWOT分析
    Lamprell Plc (LAM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Explor Resources Inc.:企業のM&A・事業提携・投資動向
    Explor Resources Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Explor Resources Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆